US20020055177A1
(en)
*
|
1999-03-10 |
2002-05-09 |
Glaxo Wellcome Inc. |
Compound and its use
|
AU763244B2
(en)
*
|
2000-01-03 |
2003-07-17 |
Rpg Life Sciences Limited |
A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
|
US6653481B2
(en)
|
2000-12-29 |
2003-11-25 |
Synthon Bv |
Process for making amlodipine
|
MXPA03005885A
(es)
|
2000-12-29 |
2005-04-19 |
Pfizer Ltd |
Procedimiento para fabricar maleato de amlodipina.
|
ATE315026T1
(de)
|
2000-12-29 |
2006-02-15 |
Pfizer Ltd |
Amlodipin-hemimaleat
|
CA2433284A1
(fr)
*
|
2000-12-29 |
2002-07-11 |
Pfizer Limited |
Standards de reference destines a la determination de la purete ou de la stabilite de maleate d'amlodipine et procedes correspondants
|
CA2433191A1
(fr)
|
2000-12-29 |
2002-07-11 |
Pfizer Limited |
Derive aspartate de l'amlodipine utilise comme antagoniste des canaux calciques
|
AT5874U1
(de)
|
2000-12-29 |
2003-01-27 |
Bioorg Bv |
Pharmazeutische zubereitungen enthaltend amlodipinmaleat
|
US7335380B2
(en)
|
2000-12-29 |
2008-02-26 |
Synthon Ip Inc. |
Amlodipine free base
|
EP1309556B1
(fr)
|
2000-12-29 |
2004-11-24 |
Pfizer Limited |
Fumarate d'amlodipine
|
BR0116554A
(pt)
|
2000-12-29 |
2004-02-03 |
Pfizer Ltd |
Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
|
MXPA03005882A
(es)
|
2000-12-29 |
2005-04-19 |
Pfizer Ltd |
Derivado amida de amlodipina.
|
DE10134980C2
(de)
*
|
2001-07-17 |
2003-05-28 |
Helm Ag |
Verfahren zur Herstellung von Lamotrigin
|
CA2366521C
(fr)
|
2001-12-24 |
2007-03-06 |
Brantford Chemicals Inc. |
Un procede nouveau et efficace de preparation de lamotrigine et d'autres 3,5-diamino-1,2,4-triazines substituees en position 6
|
IL164155A0
(en)
*
|
2002-03-20 |
2005-12-18 |
Teva Pharma |
Crystalline forms of quetiapine hemifumarate
|
HU225667B1
(en)
|
2002-09-20 |
2007-05-29 |
Richter Gedeon Nyrt |
Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
|
ES2209639B1
(es)
|
2002-10-31 |
2005-08-01 |
Vita Cientifica, S.L. |
Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
|
GB2395483A
(en)
*
|
2003-07-03 |
2004-05-26 |
Jubilant Organosys Ltd |
Crystalline lamotrigine and its monohydrate
|
CA2657076A1
(fr)
|
2003-08-28 |
2005-03-17 |
Teva Pharmaceutical Industries Ltd. |
Procede de preparation de sels calciques de rosuvastatine
|
CA2546701C
(fr)
*
|
2003-11-24 |
2010-07-27 |
Teva Pharmaceutical Industries Ltd. |
Sels d'ammonium cristallins de la rosuvastatine
|
WO2005056534A1
(fr)
*
|
2003-12-02 |
2005-06-23 |
Teva Pharmaceutical Industries Ltd. |
Norme de reference pour la caracterisation de la rosuvastatine
|
US7851624B2
(en)
*
|
2003-12-24 |
2010-12-14 |
Teva Pharamaceutical Industries Ltd. |
Triol form of rosuvastatin and synthesis of rosuvastatin
|
WO2005075427A2
(fr)
*
|
2004-01-30 |
2005-08-18 |
Teva Pharmaceutical Industries Ltd. |
Montelukast de sodium polymorphe
|
KR20060117356A
(ko)
*
|
2004-01-30 |
2006-11-16 |
테바 파마슈티컬 인더스트리즈 리미티드 |
몬테루카스트 유리산 다형체
|
MD2823G2
(ro)
*
|
2004-02-12 |
2006-05-31 |
Институт Химии Академии Наук Молдовы |
Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
|
WO2005105751A1
(fr)
*
|
2004-04-21 |
2005-11-10 |
Teva Pharmaceutical Industries Ltd. |
Procedes de preparation de sodium montelukast
|
US7683188B2
(en)
|
2004-04-26 |
2010-03-23 |
TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság |
Process for preparation of mycophenolic acid and ester derivatives thereof
|
US20050250773A1
(en)
*
|
2004-04-27 |
2005-11-10 |
Sandor Molnar |
Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
|
EP1687254A2
(fr)
*
|
2004-06-28 |
2006-08-09 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Procede pour la resolution optique et le recyclage de tamoxetine
|
US7439399B2
(en)
*
|
2004-06-28 |
2008-10-21 |
Teva Pharmaceutical Fine Chemicals |
Processes for the preparation of atomoxetine hydrochloride
|
WO2006017357A1
(fr)
*
|
2004-07-13 |
2006-02-16 |
Teva Pharmaceutical Industries Ltd. |
Procede pour la preparation de rosuvastatine mettant en oeuvre une etape d'oxydation par tempo
|
US7439373B2
(en)
*
|
2004-07-20 |
2008-10-21 |
TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság |
Crystalline mycophenolate sodium
|
CA2568629A1
(fr)
*
|
2004-07-22 |
2006-02-23 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Polymorphes du chlorhydrate d'atomoxetine
|
US7629461B2
(en)
*
|
2004-09-04 |
2009-12-08 |
Teva Pharmaceutical Industries Ltd |
Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
|
US20060081361A1
(en)
*
|
2004-09-13 |
2006-04-20 |
Gabbey Lawrence W |
Oil cooler with integral filter
|
CA2579997A1
(fr)
*
|
2004-09-28 |
2006-04-06 |
Teva Pharmaceutical Industries Ltd. |
Procede de preparation de formes d'atorvastatine calcique sensiblement exemptes d'impuretes
|
WO2006045120A2
(fr)
*
|
2004-10-19 |
2006-04-27 |
Teva Pharmaceutical Industries Ltd. |
Purification du maleate de tegaserod
|
US7678551B2
(en)
*
|
2004-10-25 |
2010-03-16 |
Seradyn, Inc. |
Immunoassays for lamotrigine
|
JP2007523213A
(ja)
*
|
2004-12-23 |
2007-08-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
|
PT1836157E
(pt)
*
|
2005-01-11 |
2009-11-24 |
Teva Pharm Fine Chemicals Srl |
Polimorfos de cloridrato de memantina
|
US20070167625A1
(en)
*
|
2005-02-22 |
2007-07-19 |
Anna Balanov |
Preparation of rosuvastatin
|
US20070037979A1
(en)
*
|
2005-02-22 |
2007-02-15 |
Valerie Niddam-Hildesheim |
Preparation of rosuvastatin
|
JP4713574B2
(ja)
|
2005-02-22 |
2011-06-29 |
テバ ファーマシューティカル インダストリーズ リミティド |
ロスバスタチンアルキルエーテルを含まないロスバスタチンおよびその塩およびそれらを製造する方法
|
US7291614B2
(en)
*
|
2005-02-24 |
2007-11-06 |
Teva Pharmaceutical Industries Ltd. |
Processes for the preparation of linezolid intermediate
|
EP1858859A1
(fr)
*
|
2005-03-14 |
2007-11-28 |
Teva Pharmaceutical Industries Ltd. |
Procede de preparation du compose optiquement actif (s)-(+)-n,n-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamine
|
WO2006108120A1
(fr)
*
|
2005-04-05 |
2006-10-12 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Chlorhydrate d’atomoxetine stable, procede de preparation dudit chlorhydrate d’atomoxetine et controle analytique de sa stabilite
|
CN101160281A
(zh)
*
|
2005-04-06 |
2008-04-09 |
特瓦制药工业有限公司 |
结晶形态的普瑞巴林
|
US7488846B2
(en)
*
|
2005-04-11 |
2009-02-10 |
Teva Pharmaceuical Industries Ltd. |
Pregabalin free of lactam and a process for preparation thereof
|
MX2007012606A
(es)
*
|
2005-04-11 |
2008-01-11 |
Teva Pharma |
Proceso para elaborar (s)-pregabalina.
|
CA2603795A1
(fr)
*
|
2005-04-14 |
2006-10-26 |
Teva Pharmaceutical Industries Ltd. |
Processus de preparation de fumarate de quetiapine
|
US20080281111A1
(en)
*
|
2005-04-26 |
2008-11-13 |
Sandor Molnar |
Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
|
WO2006121557A1
(fr)
*
|
2005-05-10 |
2006-11-16 |
Teva Pharmaceutical Industries Ltd. |
Pregabaline exempte de lactame et son procede de preparation
|
JP2008505980A
(ja)
*
|
2005-05-10 |
2008-02-28 |
テバ ファーマシューティカル インダストリーズ リミティド |
イソブチルグルタル酸を有さないプレガバリン及びその調製方法
|
CA2604624A1
(fr)
*
|
2005-05-10 |
2006-11-16 |
Teva Pharmaceutical Industries Ltd. |
Resolution optique de l'acide 3-carbamoylmethyl-5-methyl hexanoique
|
EP1879851B1
(fr)
*
|
2005-05-10 |
2010-11-03 |
Teva Pharmaceutical Industries Ltd |
Procede pour preparer de la pregabaline et des sels de celle-ci
|
ATE445587T1
(de)
|
2005-05-23 |
2009-10-15 |
Teva Pharma |
Verfahren zur herstellung von cinacalcet hydrochlorid kristallform i
|
CA2606945A1
(fr)
*
|
2005-06-27 |
2007-01-04 |
Sicor, Inc. |
Impurete d'un intermediaire de l'anastrozole, et ses applications
|
BRPI0605902A
(pt)
*
|
2005-06-27 |
2007-12-18 |
Sicor Inc |
processo de purificação para intermediário de anastrozol
|
EP1904448B1
(fr)
*
|
2005-07-05 |
2011-02-02 |
Teva Pharmaceutical Industries, Ltd. |
Purification du montélukast
|
EP1805148A2
(fr)
*
|
2005-08-16 |
2007-07-11 |
Teva Pharmaceutical Industries Ltd. |
Intermediaire de rosuvastatine sous forme cristalline
|
CA2619472A1
(fr)
*
|
2005-09-19 |
2007-03-29 |
Teva Pharmaceutical Industries Ltd. |
Acides 3-carbamoylmethyl-5-methylhexanoiques chiraux, intermediaires cles pour la nouvelle synthese de la (s)-pregabaline
|
US20070197529A1
(en)
*
|
2005-12-01 |
2007-08-23 |
Viviana Braude |
Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
|
WO2007067581A1
(fr)
|
2005-12-05 |
2007-06-14 |
Teva Pharmaceutical Industries Ltd. |
2-(n-methyl-propanamine)-3-(2-naphtol)thiophene, une impurete du duloxetine chlorhydrate
|
WO2007069264A2
(fr)
*
|
2005-12-15 |
2007-06-21 |
Alembic Limited |
Nouveaux composes
|
EP1966179A2
(fr)
*
|
2005-12-27 |
2008-09-10 |
Teva Pharmaceutical Industries Ltd |
Bromhydrate de darifenacine pur sensiblement exempt de darifenacine oxydee, sels de celui-ci, et procedes de preparation de ceux-ci
|
EP1999100A1
(fr)
*
|
2006-03-27 |
2008-12-10 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Procédé de synthèse de chlorhydrate de mémantine ne contenant essentiellement aucune impureté
|
US20080146675A1
(en)
*
|
2006-04-05 |
2008-06-19 |
Eugenio Castelli |
Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
|
GB0609835D0
(en)
*
|
2006-05-18 |
2006-06-28 |
Pliva Istrazivanje I Razvoj D |
Impurities of a pharmaceutical product
|
TW200815323A
(en)
*
|
2006-05-24 |
2008-04-01 |
Teva Pharma |
Processes for the preparation of R-(+)-3-(carbamoylmethyl)-5-methylhexanoic acid and salts thereof
|
EP2071032A3
(fr)
*
|
2006-05-31 |
2009-07-08 |
Teva Pharmaceutical Industries Ltd |
Utilisation d'une résolution enzymatique pour la préparation d'intermédiaires de la prégabaline
|
US20080015385A1
(en)
*
|
2006-05-31 |
2008-01-17 |
Lilach Hedvati |
Preparation of (S)-pregabalin-nitrile
|
DE602007004728D1
(de)
*
|
2006-06-29 |
2010-03-25 |
Ivax Pharmaceuticals Sro |
Regulation der säuremetabolitproduktion
|
US20120142919A1
(en)
*
|
2006-08-02 |
2012-06-07 |
Medichem, S.A. |
Method for synthesizing lamotrigine
|
EP2054396A1
(fr)
*
|
2006-08-14 |
2009-05-06 |
Lonza Ag |
Procédé de préparation de lamotrigine
|
US20080242877A1
(en)
*
|
2007-02-26 |
2008-10-02 |
Vinod Kumar Kansal |
Intermediates and processes for the synthesis of Ramelteon
|
BRPI0803092A2
(pt)
*
|
2007-03-22 |
2011-08-30 |
Teva Pharma |
sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina
|
TW200904982A
(en)
*
|
2007-04-11 |
2009-02-01 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Method for reducing impurity level in mycophenolic acid fermentation
|
EP2098519A1
(fr)
*
|
2007-05-31 |
2009-09-09 |
Teva Pharmaceutical Industries Ltd. |
Procédé de synthèse du rameltéon et ses intermédiaires
|
US20090137842A1
(en)
*
|
2007-10-03 |
2009-05-28 |
Vollerner Yuri |
Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
|
EP2508523B2
(fr)
*
|
2007-10-23 |
2019-04-17 |
Teva Pharmaceutical Industries Ltd. |
Polymorphes de dasatinib et leur procédé de préparation
|
WO2009056993A2
(fr)
*
|
2007-11-01 |
2009-05-07 |
Teva Pharmaceutical Industries Ltd. |
Procédé de synthèse de rameltéon et intermédiaires de ce dernier
|
WO2009061513A1
(fr)
*
|
2007-11-09 |
2009-05-14 |
Thar Pharmaceuticals |
Formes cristallines de lamotrigine
|
WO2009151494A1
(fr)
*
|
2008-03-06 |
2009-12-17 |
Teva Pharmaceutical Industries Ltd. |
Procédés de préparation de la o-desméthylvenlafaxine, exempte de ses impuretés dimères
|
KR20100107500A
(ko)
*
|
2008-06-23 |
2010-10-05 |
테바 파마슈티컬 인더스트리즈 리미티드 |
(s) 또는 (r)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법
|
US20100152468A1
(en)
*
|
2008-10-16 |
2010-06-17 |
Teva Pharmaceutical Industries Ltd. |
Process for the synthesis of ramelteon and its intermediates
|
CA2795023A1
(fr)
*
|
2010-03-29 |
2011-10-06 |
Pliva Hrvatska D.O.O. |
Formes cristallines du fumarate de o-desmethylvenlafaxine
|
WO2012034065A1
(fr)
|
2010-09-09 |
2012-03-15 |
Teva Pharmaceutical Industries Ltd. |
Intermédiaires d'aliskirène et procédé destiné à analyser la pureté de l'aliskirène
|
CN102766104A
(zh)
*
|
2012-08-20 |
2012-11-07 |
三金集团湖南三金制药有限责任公司 |
一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
|
WO2015092819A2
(fr)
*
|
2013-12-21 |
2015-06-25 |
Nektar Therapeutics (India) Pvt. Ltd. |
Dérivés de 6- (2,3-dichlorophényl) -1,2,4-triazin -5-amine
|
CN110467560A
(zh)
|
2018-05-09 |
2019-11-19 |
深圳微芯生物科技股份有限公司 |
一种苯基氨基丙酸钠衍生物、其制备方法和应用
|
KR102270026B1
(ko)
*
|
2020-01-31 |
2021-06-28 |
현대약품 주식회사 |
(3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
|
CN113156009B
(zh)
*
|
2021-04-20 |
2023-12-22 |
三金集团湖南三金制药有限责任公司 |
高效液相色谱分析拉莫三嗪的方法
|